The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...

Lupin has received the Food and Drug Administration’s green light for rivaroxaban tablets, in 10 mg, 15 mg and 20 mg, which is the generic of Janssen’s Xarelto. This product will be manufactured at ...

Aurobindo has obtained the Food and Drug Administration’s green light for rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. Rivaroxaban tablets are used to reduce the risk of ...

A new oral suspension formulation of Xarelto has also been approved by the FDA. The Food and Drug Administration (FDA) has approved Xarelto ® (rivaroxaban) for 2 new pediatric indications: treatment ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...

Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer. Treatment or prevention of thrombosis poses an ...

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner rivaroxaban for a blood clot in the left ventricle did as well as similar ...

In 2025, the FDA approved 73 first-time generic drugs. Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

A win in patent court in Europe last October was a pleasant surprise for Bayer, giving its heart drug Xarelto an additional two years of exclusivity—all the way to 2026. But the generics ship already ...

After a tough showing earlier this year, Bayer has logged another Xarelto downturn in the second quarter. The aging blood thinner continues to feel the squeeze from an aggressive drug discounting ...